Evidence map›Paper›PMID 38894643›Full record

ReviewGlia2025

How omics is revealing new roles for glia in addiction.

David J Bergkamp, John F Neumaier

Abstract readReview
In one paragraph

Review in Glia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

David J BergkampDepartment of Pharmacology, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-6314-5544
John F NeumaierDepartment of Pharmacology, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-1763-7118

Funding

Microglia and Opioid Withdrawal: Mechanisms of Negative ReinforcementR01DA052618 · NIDA · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · PI NEUMAIER, JOHN F · 2021 to 2025
$1.9M
NIDA NIH HHS R01 DA052618NIDA NIH HHS R01DA052618
6 · The paper itself

Abstract

Experiments to study the biology of addiction have historically focused on the mechanisms through which drugs of abuse drive changes in the functioning of neurons and neural circuits. Glia have often been ignored in these studies, however, and this has left many questions in the field unanswered, particularly, surrounding how glia contribute to changes in synaptic plasticity, regulation of neuroinflammation, and functioning of neural ensembles given massive changes in signaling across the CNS. Omics methods (transcriptomics, translatomics, epigenomics, proteomics, metabolomics, and others) have expanded researchers' abilities to generate hypotheses and carry out mechanistic studies of glial cells during acquisition of drug taking, intoxication, withdrawal, and relapse to drug seeking. Here, we present a survey of how omics technological advances are revising our understanding of astrocytes, microglia, oligodendrocytes, and ependymal cells in addiction biology.

Indexed as

GenomicsMetabolomicsNeurogliaSubstance-Related DisordersAnimalsHumansProteomicsalcoholastrocytescocainemicrogliaoligodendrocytesomicsopioid

Identifiers

PMID38894643
PMCPMC12751529

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.